https://doi.org/10.30702/Ophthalmology27082021-14.3.08-17/002.1-022
UDC 617.713-002+617.711-002.1-022-085

Oleksandra V. Zborovska, Ilijna S. Horyanova, Victoria V. Kolesnichenko

The Filatov Institute of Eye Diseases and Tissue Therapy of The National Academy of Medical Sciences of Ukraine, Odesa, Ukraine

Abstract

The aim. To increase the effectiveness of treatment of dry eye syndrome in patients with Sjogren’s syndrome with preservative-free drops which contain 0.4 % sodium hyaluronate and nutraceutical complexes nutraceuticals.

Materials and methods. The study was conducted on the basis of the Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine. The study included 64 patients aged 34 to 58 years (128 eyes) with dry eye syndrome accompanied by Sjogren’s syndrome. Examination of patients included: assessment of complaints, visometry, refractometry, bacterial culture of the conjunctiva and nasopharynx, biomicroscopy, ophthalmoscopy, Schirmer and Norn tests, assessment of "comfort of application of drops" on the questionnaire. This study is an extension of the study previously conducted at the premises of the Filatov Institute of Eye Diseases and Tissue Therapy of The National Academy of Medical Sciences of Ukraine on the effectiveness of preservative-free eye drops containing 0.4 % hyaluronic acid in the treatment of Sjogren’s syndrome.

Results. Prior to the appointment of comprehensive treatment with instillations, the Norn test showed 6.55 s (SD 1.57) with a minimum of 3 s, a maximum of 9 s, and a median of 6.5 s. After 3 months of treatment the Norn test score in the 1st group averaged 14.66 (SD 1.07) vs. 13.86 (SD 1.07) in the 2nd group, but the difference was not statistically significant (p=1.0). The mean number of required instillations per day was 4.1 (SD 1.04) in the 1st group and 5.27 (SD 1.11) in the 2nd group.

Conclusion. Instillations of preservative-free drops containing sodium hyaluronate 0.4 % (in a bottle with an innovative ophthalmic squeeze dispenser (OSD)) in combination with a nutraceutical complex in the treatment of dry eye syndrome in patients with Sjogren’s syndrome is effective and allows achieving a stable and long-term effect.

Keywords: Sjogren’s syndrome, hyaluronic acid, nutraceuticals, artificial tear, Schirmer test, Norn test, dry eye syndrome, tear film.

---

REFERENCES

1. Vasil'ev VI. [Clinical features, diagnosis and differential diagnosis of Sjogren’s disease]. Russian Medical Journal. 2008;16(10):638-648. Russian. 
2. Zborovskaya AV, Dorokhova AE, Kolesnichenko VV. [Increasing the Efficiency of Treatment of Dry Eye Syndrome in Patients with Sjogren’s Syndrome by Application of the Preparation of Preserved Drops Containing Sodium Hyaluronate 0.4%]. Ukr J Ophthalmol. 2020;1(11):15-22. Ukrainian. https://doi.org/10.30702/Ophthalmology30092020-11.1.1615-22
3. Polunin GS, Kurenkov VV, Safonova TN, Polunina YeG. [New clinical classification of dry eye syndrome]. Refraktsionnaya khirurgiya i oftalmologiya. 2003;3(3):53-56. Russian. 
4. Mirzakulova UR, Urazalin JB, Ibragimova RS, Aktasov NB, Ospanov MJ. [Diagnosis of Sjogren's syndrome]. Vestnik KazNMU. 2014;5.225-228. Russian.
5. Maychuk YuF, Yani EV. [Choice of pharmacotherapy for various clinical forms of dry eye disease]. Ophthalmology in Russia. 2012;9(4):58-64. Russian. https://doi.org/10.18008/1816-5095-2012-4-58-64
6. Vasil'ev VI, Probatova NA, Varlamova EIu, Tupitsin NN, Simonova MV, Safonova TN, Bozh'eva LA, Shornikova NS, Logvinenko OA, Belenin GIu. Prognosticheskoe znachenie smeshannoĭ monoclonal'noĭ krioglobulinemii pri bolezni Shegrena [Prognostic implications of mixed monoclonal cryoglobulinemia in Sjogren's disease]. Ter Arkh. 2004;76(8):61-8. Russian. PubMed PMID: 15471400.
7. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000 Sep;12(5):391-398. https://doi.org/10.1097/00002281-200009000-00007
8. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010 Jul 28;304(4):452-460. https://doi.org/10.1001/jama.2010.1014
9. Yamamura T, et al., inventor; PHARMACEUTICAL CO., LTD. (JP), assignee. [A thermosensitive gelling artificial tear]. Russian patent RU 2710366. 2019. 
10. Egorov AE, Eliseeva TO. [Hyaluronic acid as a component of tear substitutes]. Russian Journal of Clinical Ophthalmology. 2016;16(4):224-226. Russian. https://doi.org/10.21689/2311-7729-2016-16-4-224-226
11. Egorov EA, Romanova TB. [Influence of the components of tear substitutes on efficacy and tolerance of the treatment in patients with dry eye syndrome] Russian Journal of Clinical Ophthalmology. 2016;16(3):151-154. Russian. https://doi.org/10.21689/2311-7729-2016-16-3-151-154
12. Hamano T, Horimoto K, Lee M, Komemushi S. Sodium hyaluronate eyedrops enhance tear film stability. Jpn J Ophthalmol. 1996;40(1):62-65. PubMed PMID: 8739501.
13. Bron AJ. Duke-Elder Lecture. Prospects for the dry eye. Trans Ophthalmol Soc U K. 1985;104 ( Pt 8):801-826. PubMed PMID: 3914112.
14. Tiffany JM. Viscoelastic properties of human tears and polymer solutions. Adv Exp Med Biol. 1994;350:267-270. https://doi.org/10.1007/978-1-4615-2417-5_45
15. Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE. A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology. 2017 Jan;124(1):43-52. https://doi.org/10.1016/j.ophtha.2016.09.023
16. Chen M, Hu DN, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res. 2010 Mar;90(3):437-443. https://doi.org/10.1016/j.exer.2009.12.004
17. Beharry KD, Cai CL, Siddiqui F, Chowdhury S, D'Agrosa C, Valencia GB, Aranda JV. Comparative Effects of Coenzyme Q10 or n-3 Polyunsaturated Fatty Acid Supplementation on Retinal Angiogenesis in a Rat Model of Oxygen-Induced Retinopathy. Antioxidants (Basel). 2018 Nov 9;7(11):160. https://doi.org/10.3390/antiox7110160
18. Ramos-Casals M, Brito-Zerón P, Solans R, Camps MT, Casanovas A, Sopeña B, Díaz-López B, et al. Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford). 2014 Feb;53(2):321-31. https://doi.org/10.1093/rheumatology/ket349